NCT05740488View on ClinicalTrials.gov

Efficacy and Safety of Apalutamide in Combination With 89Sr as Neoadjuvant Therapy in Prostate Cancer With ≤10 Bone Metastases

NARecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 7, 2022

Primary Completion Date

April 30, 2025

Study Completion Date

December 31, 2025

Conditions
Prostate Cancer With ≤10 Bone Metastases
Interventions
DRUG

Apalutamide

240mg, po, qd

DRUG

89Sr

100\~150MBq(based on weight), iv, q90d

DRUG

Luteinizing Hormone-Releasing Hormone Analog

sc, 3.6mg, q30d or 10.8mg, q90d

Trial Locations (1)

510200

RECRUITING

zhujiang Hospital of Southern Medical University, Guangzhou

All Listed Sponsors
lead

Zhujiang Hospital

OTHER